I spend a lot of time talking about the most common forms of Neuroendocrine Tumours (NETs), but what about the less well-known types? As part of my commitment to all types of NETs, I'd like to shine a light on two less common tumour types known as Pheochromocytomas and Paragangliomas - incidence rate approximately 8 per million per year. They are normally grouped together and the definitions below will confirm…
I recently met a colleague who I hadn’t seen for 30 years. He was more than just a colleague, he was once my ‘Commanding Officer’. He had been made aware of my illness but after asking how I was, he was content with my short explanation “I’m not dead yet“. The great thing about soldiery is that you can pick up where you left off 30 years ago as if it was only yesterday and ‘bravado’ is not only allowed, it’s expected…
LONG ACTING LANREOTIDE (LEFT) – LONG ACTING OCTREOTIDE (RIGHT)
Somatostatin Analogues are the ‘workhorse’ treatments for those living with NETs, particularly where syndromes are involved. Although it can sometimes seem like they are only associated with serotonin releasing tumours (i.e. what might be described as Carcinoid), these types of drugs can be used to help with other NET types including Pancreatic…
A fairly common disposition of metastatic Neuroendocrine Tumours (NETs) is a primary with associated local/regional secondary’s (e.g. lymph nodes, mesentery and others) with liver metastases. Technically speaking, the liver is distant. However, many metastatic patients have additional and odd appearances in even more distant places, including (but not limited to) the extremities and the head & neck. In certain NETs…
Here’s some extracts from the CEO of Advanced Accelerator Applications 2016 Progress Report published on 9 Jan 2017. I’ve added additional comment where necessary to provide a richer picture. There is some really useful information, particularly for those looking for updates on PRRT (Lutathera®). I found the content very positive and let me say that the header to the report was entitled “….Asserts Confidence…
